300 Participants Needed

AVD-104 for Age-Related Macular Degeneration

(SIGLEC Trial)

Recruiting at 56 trial locations
DP
DC
KM
KM
Overseen ByKeri Marchitto
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Aviceda Therapeutics, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is AVD-104 safe for humans?

The safety of anti-VEGF treatments, like bevacizumab, for age-related macular degeneration has been studied, showing some concerns about non-eye-related side effects, especially in people with heart conditions. However, these treatments are generally considered safe for most patients.12345

What data supports the effectiveness of the drug AVD-104 for age-related macular degeneration?

Research shows that anti-VEGF (antivascular endothelial growth factor) injections, similar to AVD-104, have been effective in treating age-related macular degeneration by improving vision and reducing disease progression.678910

Who Is on the Research Team?

DC

David Callanan, MD

Principal Investigator

Aviceda Therapeutics

Are You a Good Fit for This Trial?

This trial is for people with a specific eye condition called Geographic Atrophy (GA) due to Age-Related Macular Degeneration (AMD). Participants must have certain levels of vision clarity, as measured by an eye chart. They should not have the wet form of AMD or other eye conditions that might need treatment during the study.

Inclusion Criteria

My eye condition can be fully seen and imaged without touching the optic nerve area.
I have been diagnosed with a type of age-related macular degeneration that does not affect the center of my vision.
Part 1: BCVA in the study eye using ETDRS Chart Visual Acuity Scale (VAS) of 5 to 55 letters (equivalent to Snellen VA of approximately 20/800 - 20/80)
See 3 more

Exclusion Criteria

I don't have eye conditions needing surgery other than GA from AMD.
I have wet AMD or CNV diagnosed by specific eye scans.
My study eye has specific eye conditions.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Part 1: Single Dose Treatment

Participants receive a single intravitreal injection of AVD-104 at one of 4 escalating doses and are followed for safety observation.

3 months
1 visit (in-person) for injection, followed by regular safety visits

Part 2: Multiple Dose Treatment

Participants are randomized to receive either high dose AVD-104 bimonthly, low dose AVD-104 monthly, or avacincaptad monthly for 24 months.

24 months
Bimonthly or monthly visits (in-person) for injections

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 months

What Are the Treatments Tested in This Trial?

Interventions

  • AVD-104
  • Sham injection
Trial Overview The study tests multiple doses of AVD-104, given through injections into the eye, to see if it's safe and effective for treating GA in AMD patients. Some participants will receive a sham injection instead to serve as a comparison group.
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Active Control
Group I: Part 1Experimental Treatment1 Intervention
Group II: Part 2: High dose AVD-104Active Control1 Intervention
Group III: Part 2: AvacincaptadActive Control1 Intervention
Group IV: Part 2: Low dose AVD-104Active Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Aviceda Therapeutics, Inc.

Lead Sponsor

Trials
2
Recruited
320+

Published Research Related to This Trial

In a study of 1017 patients treated with intravitreal ranibizumab for neovascular age-related macular degeneration (AMD) over 4 years, 50% of patients maintained a vision level of 6/18 or better, indicating significant long-term efficacy of the treatment.
The average number of injections required increased over time, with patients receiving approximately 13.7 injections by the end of the 4-year period, highlighting the ongoing need for treatment and the importance of long-term follow-up in managing AMD.
Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration.Pushpoth, S., Sykakis, E., Merchant, K., et al.[2015]
In a study of 223 patients with neovascular age-related macular degeneration (nAMD) receiving anti-VEGF injections for over 5 years, there was no significant difference in best visual acuity (BVA) changes based on macular atrophy (MA) status.
Both groups, regardless of MA presence, experienced similar visual outcomes after 5 to 7 years of treatment, indicating that baseline MA status does not affect the effectiveness of anti-VEGF therapy in improving vision.
Long-Term Visual Outcomes in Neovascular Age-Related Macular Degeneration Eyes With Baseline Macular Atrophy on Anti-Vascular Endothelial Growth Factor Treatment.Foster, MJ., Shaia, J., Maatouk, CM., et al.[2023]
Only about 0.1% of the Polish population requires treatment for neovascular age-related macular degeneration (nAMD) when considering patients without severe irreversible eye damage, indicating a relatively low prevalence of this condition needing intervention.
The COVID-19 pandemic significantly impacted the enrollment in the national AMD therapeutic program, with a notable decrease in monthly enrollments, highlighting potential barriers to treatment access during health crises.
The Need for Treatment of Neovascular Age-Related Macular Degeneration: A Study Based on the Polish National Registry.Teper, SJ., Nowińska, A., Figurska, M., et al.[2022]

Citations

Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. [2020]
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients. [2015]
Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. [2015]
Long-Term Visual Outcomes in Neovascular Age-Related Macular Degeneration Eyes With Baseline Macular Atrophy on Anti-Vascular Endothelial Growth Factor Treatment. [2023]
The Need for Treatment of Neovascular Age-Related Macular Degeneration: A Study Based on the Polish National Registry. [2022]
Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis. [2018]
Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology. [2022]
Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. [2022]
Palmerston North Interventional Rapid Avastin Treat and Extend (PIRATE) study protocol; meeting the medical retina service needs of our ageing population. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security